应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03347 泰格医药
休市中 08-23 16:08:27
28.400
-0.200
-0.70%
最高
28.950
最低
28.250
成交量
81.51万
今开
28.600
昨收
28.600
日振幅
2.45%
总市值
245.65亿
流通市值
34.97亿
总股本
8.65亿
成交额
2,328万
换手率
0.66%
流通股本
1.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
全球首款mRNA肺癌疫苗已在七国启动1期临床试验
IT之家 · 08-24 08:49
全球首款mRNA肺癌疫苗已在七国启动1期临床试验
眼科医疗需求升温 头部药企瞄准细分赛道
中证网 · 08-24 06:31
眼科医疗需求升温 头部药企瞄准细分赛道
永泰生物-B(06978)发布中期业绩 其他收入652.6万元 同比增加17.9% 计划全面推进EAL®II期临床试验的申报、生产及质量验证
智通财经 · 08-23 21:33
永泰生物-B(06978)发布中期业绩 其他收入652.6万元 同比增加17.9% 计划全面推进EAL®II期临床试验的申报、生产及质量验证
【华北制药:子公司获药物临床试验批准】金十数据8月23日讯,华北制药公告,公司下属控股子公司金坦公司于2024年8月22日收到国家药品监督管理局核准签发的四价重组诺如病毒疫苗的《药物临床试验批准通知书》。
美港电讯 · 08-23 18:12
【华北制药:子公司获药物临床试验批准】金十数据8月23日讯,华北制药公告,公司下属控股子公司金坦公司于2024年8月22日收到国家药品监督管理局核准签发的四价重组诺如病毒疫苗的《药物临床试验批准通知书》。
泰格医药08月23日获主力加仓349万元 环比增加2226.67%
市场透视 · 08-23 16:16
泰格医药08月23日获主力加仓349万元 环比增加2226.67%
【新华制药抗阿尔茨海默病创新药OAB-14顺利完成I期临床试验研究】金十数据8月23日讯,新华制药在北京召开抗阿尔茨海默病创新药OAB-14I期临床试验总结暨Ⅱ期临床试验方案专家论证会,标志着该创新药顺利完成I期临床试验研究,拟进入Ⅱ期药物临床研究阶段。
美港电讯 · 08-23 12:59
【新华制药抗阿尔茨海默病创新药OAB-14顺利完成I期临床试验研究】金十数据8月23日讯,新华制药在北京召开抗阿尔茨海默病创新药OAB-14I期临床试验总结暨Ⅱ期临床试验方案专家论证会,标志着该创新药顺利完成I期临床试验研究,拟进入Ⅱ期药物临床研究阶段。
先声药业(02096.HK)抗肿瘤候选药获准开展临床试验
阿斯达克财经 · 08-23 01:36
先声药业(02096.HK)抗肿瘤候选药获准开展临床试验
【华纳药厂:ZG-002片获药物临床试验批准通知书】金十数据8月22日讯,华纳药厂晚间公告,近日,公司控股子公司致根医药收到国家药品监督管理局核准签发的关于ZG-002片的《药物临床试验批准通知书》。
美港电讯 · 08-22 21:24
【华纳药厂:ZG-002片获药物临床试验批准通知书】金十数据8月22日讯,华纳药厂晚间公告,近日,公司控股子公司致根医药收到国家药品监督管理局核准签发的关于ZG-002片的《药物临床试验批准通知书》。
先声药业(02096.HK):SIM0508(Polθ小分子抑制剂)获国家药品监督管理局签发药物临床试验批准通知书
格隆汇 · 08-22 20:17
先声药业(02096.HK):SIM0508(Polθ小分子抑制剂)获国家药品监督管理局签发药物临床试验批准通知书
先声药业(02096)自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508获批开展临床试验
智通财经 · 08-22 20:15
先声药业(02096)自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508获批开展临床试验
新华制药最新公告:OAB-14干混悬剂完成I期临床试验研究
证券之星 · 08-22 19:09
新华制药最新公告:OAB-14干混悬剂完成I期临床试验研究
【新华制药:OAB-14干混悬剂临床试验达到预期目标】金十数据8月22日讯,新华制药公告,公司治疗轻至中度阿尔兹海默症的OAB-14干混悬剂完成I期临床试验研究,该阶段通过初步的临床药理学及人体安全性评价试验,观察人体对于新药的耐受程度和药代动力学特征,达到预期目标,拟进入Ⅱ期药物临床研究阶段。
美港电讯 · 08-22 18:38
【新华制药:OAB-14干混悬剂临床试验达到预期目标】金十数据8月22日讯,新华制药公告,公司治疗轻至中度阿尔兹海默症的OAB-14干混悬剂完成I期临床试验研究,该阶段通过初步的临床药理学及人体安全性评价试验,观察人体对于新药的耐受程度和药代动力学特征,达到预期目标,拟进入Ⅱ期药物临床研究阶段。
山东新华制药股份(00719.HK):OAB-14干混悬剂完成I期临床试验,拟进入II期研究阶段
格隆汇 · 08-22 18:30
山东新华制药股份(00719.HK):OAB-14干混悬剂完成I期临床试验,拟进入II期研究阶段
山东新华制药股份(00719):治疗轻至中度阿尔兹海默症的 OAB-14 干混悬剂完成 I 期临床试验研究
智通财经 · 08-22 18:30
山东新华制药股份(00719):治疗轻至中度阿尔兹海默症的 OAB-14 干混悬剂完成 I 期临床试验研究
华纳药厂:控股子公司致根医药ZG-002片获得药物临床试验批准通知书
中国财富通 · 08-22 17:11
华纳药厂:控股子公司致根医药ZG-002片获得药物临床试验批准通知书
华纳药厂最新公告:子公司ZG-002片获得药物临床试验批准通知书
证券之星 · 08-22 16:29
华纳药厂最新公告:子公司ZG-002片获得药物临床试验批准通知书
华纳药厂(688799.SH):ZG-002片获得药物临床试验批准通知书
智通财经 · 08-22 16:20
华纳药厂(688799.SH):ZG-002片获得药物临床试验批准通知书
港股异动 | 云顶新耀-B(01952)尾盘涨超5% 自研新型mRNA个性化肿瘤治疗性疫苗正式启动临床试验
智通财经 · 08-22 15:50
港股异动 | 云顶新耀-B(01952)尾盘涨超5% 自研新型mRNA个性化肿瘤治疗性疫苗正式启动临床试验
泰格医药(03347)下跌5.14%,报28.6元/股
金融界 · 08-22 13:44
泰格医药(03347)下跌5.14%,报28.6元/股
泰格医药盘中异动 下午盘股价大跌5.14%
市场透视 · 08-22 13:44
泰格医药盘中异动 下午盘股价大跌5.14%
加载更多
公司概况
公司名称:
泰格医药
所属市场:
SEHK
上市日期:
--
主营业务:
杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务,帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务,比如数据管理和统计分析;后勤和执行支持服务,比如临床试验现场管理;行政协助,比如患者招募;以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":28.4,"timestamp":1724400507030,"preClose":28.6,"halted":0,"volume":815146,"delay":0,"floatShares":123124800,"shares":864948570,"eps":2.5653365,"marketStatus":"休市中","marketStatusCode":7,"change":-0.2,"latestTime":"08-23 16:08:27","open":28.6,"high":28.95,"low":28.25,"amount":23275428,"amplitude":0.024476,"askPrice":28.45,"askSize":2500,"bidPrice":28.4,"bidSize":3700,"shortable":3,"etf":0,"ttmEps":2.1360935861939923,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1596729600000,"adjPreClose":28.6,"dividendRate":0.021917,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":0.7940114789089301,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":47.61,"timestamp":1724396583000,"preClose":47.76,"halted":0,"volume":3457856,"delay":0,"premium":"-45.56"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2461579745","title":"全球首款mRNA肺癌疫苗已在七国启动1期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2461579745","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461579745?lang=zh_cn&edition=full","pubTime":"2024-08-24 08:49","pubTimestamp":1724460598,"startTime":"0","endTime":"0","summary":"IT之家 8 月 24 日消息,英国卫报昨日发布博文,全球首款 mRNA 肺癌疫苗已经在 7 个国家和地区启动临床试验。全球首款 mRNA 肺癌疫苗名为 BNT116,由拜恩泰科公司生产,旨在治疗最常见的非小细胞肺癌,能够捕捉并杀死癌细胞,然后防止它们复发。作为 BNT116 的首次人体研究,1 期临床试验已在英国、美国、德国、匈牙利、波兰、西班牙和土耳其 7 个国家的 34 个研究机构展开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8cIkvW79mRT","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK1141","03347","BK1576","BK1583","159646"],"gpt_icon":0},{"id":"2461578151","title":"眼科医疗需求升温 头部药企瞄准细分赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2461578151","media":"中证网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461578151?lang=zh_cn&edition=full","pubTime":"2024-08-24 06:31","pubTimestamp":1724452260,"startTime":"0","endTime":"0","summary":"暑假期间,不少医院的眼科门诊迎来一波就诊小高峰。近日,记者来到复旦大学附属中山医院的近视专科门诊。“暑假期间通常是眼科门诊的旺季。最近一周大概每天接待300名左右患者,以青少年居多。”一位复旦大学附属中山医院的眼科医生告诉记者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-08-24/doc-incksvfv7462579.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-08-24/doc-incksvfv7462579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","03347","BK1141","BK1576"],"gpt_icon":0},{"id":"2461594156","title":"永泰生物-B(06978)发布中期业绩 其他收入652.6万元 同比增加17.9% 计划全面推进EAL®II期临床试验的申报、生产及质量验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2461594156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461594156?lang=zh_cn&edition=full","pubTime":"2024-08-23 21:33","pubTimestamp":1724419985,"startTime":"0","endTime":"0","summary":"智通财经APP讯,永泰生物-B 发布截至2024年6月30日止6个月业绩,该集团期内取得其他收入652.6万元,同比增加17.9%。集团计划全面推进EALII期临床试验的申报、生产及质量验证,以加快注册及获得所需数据的速度,同时提前进行未来的商业化布局。于本公告日期,公司已在北京、绍兴及上海确认建立生产中心地点。EAL于2018年9月入组第一例II期临床试验患者,且于本公告日期,公司已完成II期临床试验430名目标患者的入组工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1161","BK1576","06978","BK1141","BK1583","BK1574"],"gpt_icon":0},{"id":"2461655455","title":"【华北制药:子公司获药物临床试验批准】金十数据8月23日讯,华北制药公告,公司下属控股子公司金坦公司于2024年8月22日收到国家药品监督管理局核准签发的四价重组诺如病毒疫苗的《药物临床试验批准通知书》。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461655455","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461655455?lang=zh_cn&edition=full","pubTime":"2024-08-23 18:12","pubTimestamp":1724407958,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0191","159646","03347","BK1576","BK1583","BK1141","BK0028","BK0239","600812"],"gpt_icon":0},{"id":"2461560835","title":"泰格医药08月23日获主力加仓349万元 环比增加2226.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461560835","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461560835?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:16","pubTimestamp":1724400993,"startTime":"0","endTime":"0","summary":"08月23日, 泰格医药股价跌0.70%,报收28.40元,成交金额2327万元,换手率0.66%,振幅2.45%,量比0.79。泰格医药今日主力资金净流入349万元,上一交易日主力净流入15万元,今日环比增加2226.67%。该股近5个交易日下跌11.70%,主力资金累计净流入596万元;近20日主力资金累计净流入4092万元,其中净流入天数为14日。该股主力净额占比0.10%,港股市场排名39/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231617529f4b60ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231617529f4b60ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","03347","BK1583"],"gpt_icon":0},{"id":"2461995538","title":"【新华制药抗阿尔茨海默病创新药OAB-14顺利完成I期临床试验研究】金十数据8月23日讯,新华制药在北京召开抗阿尔茨海默病创新药OAB-14I期临床试验总结暨Ⅱ期临床试验方案专家论证会,标志着该创新药顺利完成I期临床试验研究,拟进入Ⅱ期药物临床研究阶段。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461995538","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461995538?lang=zh_cn&edition=full","pubTime":"2024-08-23 12:59","pubTimestamp":1724389144,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","BK1576","159992","BK1161","BK1141","03347","06978","BK0239","000756","BK1583","BK0164"],"gpt_icon":0},{"id":"2461325727","title":"先声药业(02096.HK)抗肿瘤候选药获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2461325727","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461325727?lang=zh_cn&edition=full","pubTime":"2024-08-23 01:36","pubTimestamp":1724348160,"startTime":"0","endTime":"0","summary":"先声药业(02096.HK) 公布,集团自主研发的抗肿瘤候选药物-小分子抑制剂SIM0508已获中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展SIM0508用于晚期实体瘤的临床试验。(de/dZ(港股报价延迟最少十五分钟。沽空资料截至 2024-08-22 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374265/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1141","BK1576","BK1583","02096","BK1191"],"gpt_icon":0},{"id":"2461317369","title":"【华纳药厂:ZG-002片获药物临床试验批准通知书】金十数据8月22日讯,华纳药厂晚间公告,近日,公司控股子公司致根医药收到国家药品监督管理局核准签发的关于ZG-002片的《药物临床试验批准通知书》。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461317369","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461317369?lang=zh_cn&edition=full","pubTime":"2024-08-22 21:24","pubTimestamp":1724333053,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","159938","09939","688799","BK1161","BK1515","BK1574","BK4551","BK0239","BK4548","BK1583","ZG","BK1576","BK4079","03347"],"gpt_icon":0},{"id":"2461319813","title":"先声药业(02096.HK):SIM0508(Polθ小分子抑制剂)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2461319813","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461319813?lang=zh_cn&edition=full","pubTime":"2024-08-22 20:17","pubTimestamp":1724329049,"startTime":"0","endTime":"0","summary":"格隆汇8月22日丨 先声药业公告,于2024年8月22日,集团自主研发的抗肿瘤候选药物-DNA聚合酶θ小分子抑制剂SIM0508已获得中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展SIM0508用于晚期实体瘤的临床试验。SIM0508在临床前研究中表现出良好的口服药代动力学性质和安全性,未观察到明显的血液学毒性,提示SIM0508与PARP抑制剂或化疗药物联用产生叠加毒性的风险较低。对多种HRD的实体瘤患者而言,SIM0508是一种潜在的有效且安全的治疗新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822201729ab5f1e0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822201729ab5f1e0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","02096","BK1583","BK1141","03347","BK1191"],"gpt_icon":0},{"id":"2461319856","title":"先声药业(02096)自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2461319856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461319856?lang=zh_cn&edition=full","pubTime":"2024-08-22 20:15","pubTimestamp":1724328918,"startTime":"0","endTime":"0","summary":"智通财经APP讯,先声药业(02096)公布,于2024年8月22日,该集团自主研发的抗肿瘤候选药物-DNA聚合酶θ(Polθ)小分子抑制剂SIM0508已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书,拟开展SIM0508用于晚期实体瘤的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","02096","03347","BK1141","BK1583","BK1191","DNA","BK1576","BK4139"],"gpt_icon":0},{"id":"2461390570","title":"新华制药最新公告:OAB-14干混悬剂完成I期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2461390570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461390570?lang=zh_cn&edition=full","pubTime":"2024-08-22 19:09","pubTimestamp":1724324967,"startTime":"0","endTime":"0","summary":"新华制药公告,公司治疗轻至中度阿尔兹海默症的OAB-14干混悬剂完成I期临床试验研究,该阶段通过初步的临床药理学及人体安全性评价试验,观察人体对于新药的耐受程度和药代动力学特征,达到预期目标,拟进入Ⅱ期药物临床研究阶段。预计年内启动OAB-14干混悬剂Ⅱ期药物临床试验。根据我国药品注册相关的法律法规要求,药物需完成临床研究并经国家药品监督管理机构审评、审批通过后方可生产上市。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200035166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK1583","BK1576","000756","BK0239","03347","BK1141"],"gpt_icon":0},{"id":"2461394197","title":"【新华制药:OAB-14干混悬剂临床试验达到预期目标】金十数据8月22日讯,新华制药公告,公司治疗轻至中度阿尔兹海默症的OAB-14干混悬剂完成I期临床试验研究,该阶段通过初步的临床药理学及人体安全性评价试验,观察人体对于新药的耐受程度和药代动力学特征,达到预期目标,拟进入Ⅱ期药物临床研究阶段。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461394197","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461394197?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:38","pubTimestamp":1724323131,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0164","BK1583","BK1576","000756","BK0239","03347","BK1141"],"gpt_icon":0},{"id":"2461271394","title":"山东新华制药股份(00719.HK):OAB-14干混悬剂完成I期临床试验,拟进入II期研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2461271394","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461271394?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:30","pubTimestamp":1724322654,"startTime":"0","endTime":"0","summary":"格隆汇8月22日丨山东新华制药股份(00719.HK)发布公告,近日,公司治疗轻至中度阿尔兹海默症的OAB-14干混悬剂完成I期临床试验研究,该阶段通过初步的临床药理学及人体安全性评价试验,观察人体对于新药的耐受程度和药代动力学特征,达到预期目标,拟进入Ⅱ期药物临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822183054ab5f16f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822183054ab5f16f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","BK1576","BK1515","00719","BK1141","03347"],"gpt_icon":0},{"id":"2461650394","title":"山东新华制药股份(00719):治疗轻至中度阿尔兹海默症的 OAB-14 干混悬剂完成 I 期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2461650394","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461650394?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:30","pubTimestamp":1724322649,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,该公司治疗轻至中度阿尔兹海默症的 OAB-14 干混悬剂(“该产品”)完成 I 期临床试验研究,该阶段通过初步的临床药理学及人体安全性评价试验,观察人体对于新药的耐受程度和药代动力学特征,达到预期目标,拟进入Ⅱ期药物临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","03347","BK1576","BK1141","00719","BK1583"],"gpt_icon":0},{"id":"2461172398","title":"华纳药厂:控股子公司致根医药ZG-002片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2461172398","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461172398?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:11","pubTimestamp":1724317873,"startTime":"0","endTime":"0","summary":"中国财富通8月22日 - 华纳药厂(688799)公告称,近日,公司控股子公司上海致根医药科技有限公司收到国家药品监督管理局核准签发的关于ZG-002片的《药物临床试验批准通知书》。ZG-002是致根医药自主开发的具有全新结构的新型抗自身免疫性疾病的药物,属于1类新药。ZG-002目前拟用于治疗中重度斑块状银屑病。临床前研究表明ZG-002有望成为新一代安全性更高、疗效更好的银屑病治疗药物,并有潜力拓展到其他的自身免疫性疾病的临床应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=mdCmNpfGn1w%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","BK4079","BK0239","BK1161","09939","BK1141","BK1574","688799","BK1515","BK1583","ZG","BK4548","BK1576","159938","BK4551"],"gpt_icon":0},{"id":"2461536234","title":"华纳药厂最新公告:子公司ZG-002片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2461536234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461536234?lang=zh_cn&edition=full","pubTime":"2024-08-22 16:29","pubTimestamp":1724315351,"startTime":"0","endTime":"0","summary":"华纳药厂公告,公司控股子公司致根医药收到国家药品监督管理局核准签发的关于ZG-002片的《药物临床试验批准通知书》。ZG-002是致根医药自主开发的新型抗自身免疫性疾病的1类新药,目前拟用于治疗中重度斑块状银屑病。根据相关法律法规要求,药物在获得临床试验批准后,需开展临床试验并经国家药监局审评、审批通过后方可生产上市。新药研发存在不确定性,投资者请谨慎决策。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200028045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688799","BK1576","BK0239","BK1583","BK1141","03347"],"gpt_icon":0},{"id":"2461364899","title":"华纳药厂(688799.SH):ZG-002片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2461364899","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461364899?lang=zh_cn&edition=full","pubTime":"2024-08-22 16:20","pubTimestamp":1724314800,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华纳药厂(688799.SH)发布公告,近日,公司控股子公司上海致根医药科技有限公司(简称“致根医药”)收到国家药品监督管理局核准签发的关于ZG-002片的《药物临床试验批准通知书》。ZG-002是致根医药自主开发的具有全新结构的新型抗自身免疫性疾病的药物,属于1类新药。ZG-002目前拟用于治疗中重度斑块状银屑病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1141","BK0239","ZG","688799","BK4079","03347","BK1576","BK4551","BK4548"],"gpt_icon":0},{"id":"2461366734","title":"港股异动 | 云顶新耀-B(01952)尾盘涨超5% 自研新型mRNA个性化肿瘤治疗性疫苗正式启动临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2461366734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461366734?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:50","pubTimestamp":1724313037,"startTime":"0","endTime":"0","summary":"消息面上,云顶新耀宣布,公司首款个性化肿瘤疫苗EVM16已正式启动研究者发起的临床试验EVM16CX01,用于评估EVM16注射液单药及联合PD-1抗体治疗在晚期或复发实体瘤受试者的安全性、耐受性、免疫原性和初步疗效的剂量递增及扩展研究,这也是EVM16首次开展人体试验。据悉,EVM16是一款云顶新耀自主研发的新型mRNA个性化肿瘤治疗性疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0737861772.HKD","LU0329678170.USD","LU2488822045.USD","BK1576","159646","BK1141","BK1574","06078","01952","BK1209","BK1583","03347","LU0329678337.USD","BK1161"],"gpt_icon":0},{"id":"2461359179","title":"泰格医药(03347)下跌5.14%,报28.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461359179","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461359179?lang=zh_cn&edition=full","pubTime":"2024-08-22 13:44","pubTimestamp":1724305467,"startTime":"0","endTime":"0","summary":"8月22日,泰格医药(03347)盘中下跌5.14%,截至13:44,报28.6元/股,成交2620.67万元。杭州泰格医药科技股份有限公司是一家提供全周期生物医药研发服务的公司,主要为全球制药和医疗器械行业提供创新研发解决方案。公司通过其100多家子公司,打造了一个覆盖全产业链的创新生态,致力于解决全球健康问题,满足患者的医疗需求。截至2024年一季报,泰格医药营业总收入16.6亿元、净利润2.35亿元。8月28日,泰格医药将披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/22134442596267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1583","BK0216","300347","LU1820825898.SGD","BK0028","BK1141","BK0077","BK0174","BK1576","LU1146622755.USD"],"gpt_icon":0},{"id":"2461592733","title":"泰格医药盘中异动 下午盘股价大跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461592733","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461592733?lang=zh_cn&edition=full","pubTime":"2024-08-22 13:44","pubTimestamp":1724305460,"startTime":"0","endTime":"0","summary":"2024年08月22日下午盘13时44分,泰格医药股票出现波动,股价快速下跌5.14%。截至发稿,该股报28.601港元/股,成交量89.16万股,换手率0.72%,振幅6.14%。资金方面,该股资金流入897.152万港元,流出1489.67万港元。泰格医药股票所在的生物技术行业中,整体跌幅为0.49%。其相关个股中,北海康成-B、同源康医药-B、来凯医药-B涨幅较大,振幅较大的相关个股有来凯医药-B、同源康医药-B、宜明昂科-B,振幅分别为15.71%、14.23%、10.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822134421a1d59629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240822134421a1d59629&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03347","BK1141","BK1576"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.1139},{"period":"1month","weight":-0.0405},{"period":"3month","weight":-0.1178},{"period":"6month","weight":0.0658},{"period":"1year","weight":-0.3371},{"period":"ytd","weight":-0.1814}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务,帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务,比如数据管理和统计分析;后勤和执行支持服务,比如临床试验现场管理;行政协助,比如患者招募;以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.100468},{"month":2,"riseRate":0.5,"avgChangeRate":-0.009723},{"month":3,"riseRate":0.75,"avgChangeRate":0.001875},{"month":4,"riseRate":0.25,"avgChangeRate":-0.034639},{"month":5,"riseRate":0.25,"avgChangeRate":-0.024615},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.082183},{"month":9,"riseRate":0.25,"avgChangeRate":-0.038233},{"month":10,"riseRate":0.5,"avgChangeRate":-0.012311},{"month":11,"riseRate":0.5,"avgChangeRate":0.046609},{"month":12,"riseRate":0.5,"avgChangeRate":0.06346}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}